Osteonecrosis of the Jaw Correlated to Bisphosphonate Therapy in Non-oncologic Patients: Clinicopathological Features of 24 Patients
Open Access
- 2 November 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (12), 2780-2787
- https://doi.org/10.3899/jrheum.090455
Abstract
Objective. Osteonecrosis of the jaws (ONJ) is a well known side effect of bisphosphonate therapies in patients with multiple myeloma or other malignancies. Its real incidence is still undetermined, and only few cases of ONJ in patients taking bisphosphonates for non-oncologic diseases have been reported. It was postulated that the clinical features, predisposing factors, and treatment outcome of this subset of patients might be different from those of oncologic patients. Methods. Over a 4 year period, a total of 102 bisphosphonate-treated patients affected by ONJ were identified. Among these, 24 patients underwent bisphosphonate therapy for non-neoplastic disease and their profile was analyzed. Results. In this study cohort, bisphosphonates had been administered mainly for postmenopausal osteoporosis (20/24 patients, 83.3%), the duration of therapy until presentation of ONJ ranging from 11 to 40 months and the most common triggering event being dentoalveolar surgery. All patients were nonsmokers; 6 manifested multiple ONJ lesions and only 3 of them had possible comorbidities. Surgical debridement was performed in 19 patients for a total of 22 lesions, which were individually considered in the followup. The latter showed complete remission of ONJ in 21/22 lesions. Conclusion. Although it might be considered a rare condition in non-oncologic patients, ONJ is a harmful side effect of bisphosphonate therapies. Clinicians must be aware of this entity, inform patients of the risks related to dental surgery, and possibly undertake adequate preventive measures.Keywords
This publication has 33 references indexed in Scilit:
- Bisphosphonates and Atrial FibrillationDrug Safety, 2009
- Reports of Esophageal Cancer with Oral Bisphosphonate UseNew England Journal of Medicine, 2009
- Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective StudyThe Oncologist, 2008
- Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literatureEuropean Journal of Internal Medicine, 2007
- Bisphosphonate-related osteonecrosis of the jaws: a comprehensive reviewJournal of Oral Pathology & Medicine, 2007
- Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 casesOral Oncology, 2006
- Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing RegimensThe Oncologist, 2004
- The antineoplastic role of bisphosphonates: from basic research to clinical evidenceAnnals of Oncology, 2003
- BisphosphonatesEndocrinology and Metabolism Clinics of North America, 2003
- Bisphosphonates: mechanisms of action.JCI Insight, 1996